Hyphens Pharma International Limited announced on Jan, 5 2026 that it has signed a licensing, supply and commercialisation agreement granting Louis Widmer SA the rights to market Cerapro MED Skin Barrier Cream in Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.

Under the agreement, Hyphens Pharma will receive an undisclosed upfront fee and customary sales-based royalties. The two companies aim to launch the pH-lowering cream in the six European markets in 2026.

Cerapro MED is a patented, CE-marked medical device formulated to lower skin pH and help restore the skin barrier in patients with atopic dermatitis.

Louis Widmer, a Swiss cosmetics and pharmaceuticals company established in 1960, will promote the product to dermatologists and paediatricians, expanding its Remederm line for dry and atopic skin.

Hyphens Pharma is a Singapore-headquartered specialty pharmaceutical and consumer healthcare group with operations across Southeast Asia.